Understanding how genetic changes affect immune responses in squamous cell carcinoma
Official title: Dissecting the genetic basis of cancer immune evasion in squamous cell carcinoma
Funded at University of Chicago · NIH-10990206 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called PIK3CA might help squamous cell carcinoma (a type of cancer) avoid the immune system, and it aims to use this information to make immunotherapy treatments work better for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $50,474 |
| NIH project number | 1F99CA294257-01 |
| Project ID | NIH-10990206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with squamous cell carcinoma, particularly those with PIK3CA mutations.
✕Less likely to help
Patients with other types of cancer or those without squamous cell carcinoma may not benefit from this research.
What this research studies
This research investigates the genetic factors that contribute to immune evasion in squamous cell carcinoma (SCC), a type of cancer that can occur in various parts of the body such as the skin and oral cavity. The study focuses on specific mutations in the PIK3CA gene, which may lead to the development of immune-resistant tumor-initiating cells. By examining how these mutations influence the behavior of cancer cells, the research aims to improve the effectiveness of immunotherapy treatments for patients with SCC. Patients may be involved in the research to help identify genetic markers that predict treatment responses.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective immunotherapy options for patients with squamous cell carcinoma.
How similar studies have gone: Previous research has shown promising results in understanding genetic factors in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Nicholson, Benjamin — University of Chicago
- Study coordinator: Nicholson, Benjamin
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.